跳至主要内容
临床试验/JPRN-UMIN000005169
JPRN-UMIN000005169已完成未知

Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with peripheral arterial disease (PAD): Examination of the therapeutic effect based on measurement of skin perfusion pressure (SPP) - Efficacy of prostaglandin E1 (alprostadil alfadex) in hemodialysis patients with PAD

Ikegami General hospital0 个研究点目标入组 40 人开始时间: 2011年3月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients with no symptoms of PAD (cold feeling, sense of numbness, intermittent claudication, pain during rest, etc.) 2. Patients under treatment with PGE1 3. Patients with symptoms of inflammatory, coronary artery, or cerebrovascular disease within the previous 3 months 4. Patients with severe hepatic or cardiac disease 5. Patients under treatment for a malignant tumor or those who had received treatment for a malignant tumor within the previous 5 years 6. Pregnant patients, lactating patients, patients who showed signs of pregnancy, and patients who intended to become pregnant 7. Patients with a history of hypersensitivity to PGE1 injection 8. Other patients who were judged to be inappropriate for the study

研究者

发起方
Ikegami General hospital

相似试验